ABBV vs. V: A Head-to-Head Stock Comparison

Updated on October 11, 2025

Here’s a clear look at ABBV and V, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ABBV	V
Company Name	AbbVie Inc.	Visa Inc.
Country	United States	United States
GICS Sector	Health Care	Financials
GICS Industry	Biotechnology	Financial Services
Market Capitalization	408.50 billion USD	681.97 billion USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	March 19, 2008
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ABBV and V by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. V: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	V
5-Day Price Return	-2.25%	1.56%
13-Week Price Return	21.31%	-1.79%
26-Week Price Return	14.68%	3.53%
52-Week Price Return	19.44%	28.33%
Month-to-Date Return	-0.13%	2.92%
Year-to-Date Return	30.13%	11.18%
10-Day Avg. Volume	7.42M	6.29M
3-Month Avg. Volume	5.67M	6.37M
3-Month Volatility	23.99%	16.68%
Beta	0.36	0.83

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

V

52.65%

Financial Services Industry

Max: 39.28%
Q3: 18.88%
Median: 9.97%
Q1: 4.03%
Min: -10.25%

V’s Return on Equity of 52.65% is exceptionally high, placing it well beyond the typical range for the Financial Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

ABBV vs. V: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

V

52.16%

Financial Services Industry

Max: 52.16%
Q3: 25.35%
Median: 12.68%
Q1: 6.11%
Min: -11.69%

A Net Profit Margin of 52.16% places V in the upper quartile for the Financial Services industry, signifying strong profitability and more effective cost management than most of its peers.

ABBV vs. V: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

V

62.21%

Financial Services Industry

Max: 75.57%
Q3: 37.78%
Median: 19.09%
Q1: 10.04%
Min: -19.42%

An Operating Profit Margin of 62.21% places V in the upper quartile for the Financial Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ABBV vs. V: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Profitability at a Glance

Symbol	ABBV	V
Return on Equity (TTM)	95.59%	52.65%
Return on Assets (TTM)	2.73%	21.39%
Net Profit Margin (TTM)	6.45%	52.16%
Operating Profit Margin (TTM)	18.80%	62.21%
Gross Profit Margin (TTM)	70.93%	80.23%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

V

1.12

Financial Services Industry

Max: 4.83
Q3: 2.70
Median: 1.44
Q1: 0.86
Min: 0.01

For the Financial Services industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

ABBV vs. V: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Financial Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

V

0.65

Financial Services Industry

Max: 5.07
Q3: 2.14
Median: 0.66
Q1: 0.12
Min: 0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Financial Services industry.

ABBV vs. V: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Financial Services industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

V

24.71

Financial Services Industry

Max: 136.23
Q3: 56.08
Median: 6.55
Q1: 2.01
Min: -33.27

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Financial Services industry.

ABBV vs. V: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	V
Current Ratio (MRQ)	0.74	1.12
Quick Ratio (MRQ)	0.48	1.06
Debt-to-Equity Ratio (MRQ)	49.22	0.65
Interest Coverage Ratio (TTM)	2.70	24.71

Growth

Revenue Growth

ABBV vs. V: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. V: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.76%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.76% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

V

0.67%

Financial Services Industry

Max: 8.12%
Q3: 3.37%
Median: 1.70%
Q1: 0.00%
Min: 0.00%

V’s Dividend Yield of 0.67% is consistent with its peers in the Financial Services industry, providing a dividend return that is standard for its sector.

ABBV vs. V: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

V

22.33%

Financial Services Industry

Max: 132.10%
Q3: 64.32%
Median: 18.23%
Q1: 0.00%
Min: 0.00%

V’s Dividend Payout Ratio of 22.33% is within the typical range for the Financial Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ABBV vs. V: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Dividend at a Glance

Symbol	ABBV	V
Dividend Yield (TTM)	2.76%	0.67%
Dividend Payout Ratio (TTM)	226.84%	22.33%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

109.30

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

At 109.30, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

V

33.45

Financial Services Industry

Max: 45.81
Q3: 30.21
Median: 16.29
Q1: 10.14
Min: 0.70

A P/E Ratio of 33.45 places V in the upper quartile for the Financial Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

ABBV vs. V: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.05

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ABBV’s P/S Ratio of 7.05 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

V

17.45

Financial Services Industry

Max: 10.88
Q3: 5.34
Median: 2.64
Q1: 1.24
Min: 0.06

The P/S Ratio is often not a primary valuation tool in the Financial Services industry.

ABBV vs. V: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Financial Services industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

V

17.81

Financial Services Industry

Max: 7.93
Q3: 3.78
Median: 1.49
Q1: 0.88
Min: 0.08

At 17.81, V’s P/B Ratio is at an extreme premium to the Financial Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ABBV vs. V: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Financial Services industry benchmarks.

Valuation at a Glance

Symbol	ABBV	V
Price-to-Earnings Ratio (TTM)	109.30	33.45
Price-to-Sales Ratio (TTM)	7.05	17.45
Price-to-Book Ratio (MRQ)	261.01	17.81
Price-to-Free Cash Flow Ratio (TTM)	22.55	30.73